A study on the clinical significance of urinary beta-aminoisobutyric acid in patients with urothelial tumours.
Urinary beta-aminoisobutyric acid (beta-AIB) has been measured in 141 patients with urothelial tumours and 60 controls. Ninetyone of the patients have been followed-up for an average period of about 2 years, which included many determinations of the beta-AIB excretion. Thirtysix patients died during the control periods. Urinary beta-AIB was found to be significantly correlated to the grade of tumour cell dysplasia, but not to the clinical tumour stage. The treatment had no major influence on the excretion. Characteristic changes in the excretion preceding high-grade tumour recurrences are demonstrated. Autopsy findings with tumour tissue in the urinary tract and distant metastases were significantly correlated to a low urinary beta-AIB in the terminal phase of the disease. The results are discussed in relation to the degradation of thymine, the dual origin of beta-AIB and the tumour-host metabolism. It is concluded, that urinary beta-AIB can contribute to the graduation of malignancy, but is not valuable as a general screening procedure for urothelial cancer.
D000368:Aged; D000621:Aminoisobutyric Acids / Q000652:urine*; D002294:Carcinoma, Squamous Cell / Q000652:urine*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000652:urine*; D008297:Male; D009364:Neoplasm Recurrence, Local; D012737:Sex Factors; D014516:Ureteral Neoplasms / Q000652:urine*; D001749:Urinary Bladder Neoplasms / Q000652:urine*
D000621:Aminoisobutyric Acids